1-3 of 3
John Newcomb
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

De Novo Design of a Miniprotein That Functions As an Adapter for CAR-T Cells and Enables Modular Tumor Targeting for the Treatment of AML

Maria Llases, Craig McKay, Sakeena Syed, Zach Caruolo, Lindsay Webb, Fred Mermelstein, Carl Novina, Nathalia Rodriguez, John Newcomb, Vitalyi Andrusyshyn, Ian Truebridge, Tessa Howard, Bobby Sandage, Edson Carcamo Noriega, Frank Teets, James Bowman, III, Xavier Michelet, Christopher Bahl
Journal: Blood
Blood (2024) 144 (Supplement 1): 7143.
https://doi.org/10.1182/blood-2024-206191
Published: 2024
Journal Articles

TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells

Wassilis S.C. Bruins, MDMSc, Wenrou Zheng, MSc, Jack P. Higgins, PhD, Erin K. Willert, PhD, John Newcomb, PhD, Ajeeta B Dash, PhD, Niels W.C.J. Van De Donk, MD PhD, Sonja Zweegman, MDPhD, Tuna Mutis, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-136928
Published: 2020
Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1867.
https://doi.org/10.1182/blood-2019-125629
Published: 2019